SPINT2

Across TCGA pan-cancer cohorts, SPINT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPINT2 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SPINT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPINT2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where SPINT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.628	0.850	.001	37	view →
PDAC	DFS	Tertile	All	0.633	0.903	.003	12	view →
HNSC	DFS	Median	II,III,IV	0.965	0.906	.036	9	view →
CCRCC	OS	Median	IV	0.167	0.784	.038	3	view →
LSCC	DFS	Tertile	II,III,IV	0.540	1.000	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPINT2–LUAD (DFS)

Open the LUAD breakdown →